Valeant Pharmaceuticals International, Inc. (NYSE:VRX) closed its last session at $23.25 with the change of -1.02%. The market capitalization of the company is $7.98B with an average Volume of 30.62 million shares. The stock currently has its 52-Week High range of $263.81 and 52-week low range of $18.55. The Price to Book (P/B) ratio stands at 1.42. The stock traded total quantity of 22.22 million shares.
For the current Fiscal Quarter, 1.83 analysts have given an average earnings per share forecast of $1.3. The Low Earnings per share estimate of the current Quarter is $2.56 and High Estimate is set at $3 according to these Analysts opinions. The Previous Year EPS of this Quarter is $0.19.
According to 12 analysts, an average sales Estimate of the current Fiscal quarter is $2.47B. The lower sales estimate is $2.30B and higher sales estimate is $2.56B according to these Analysts thoughts.
The Company currently has Highest Price Target of $175 and Lowest Price Target of $11. It has Median Price Targets of $33.5. Mean price target is set at $42.89 after consensus analysis of 18 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 3 analysts have assigned this stock as Strong Buy where 2 assigned Buy, 10 analysts believe it’s a Hold, 4 said Underperform and 1 assigned Sell rating.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended its last trade at $9.14 with the move of +2.93%. The company has market value of $1.25B with the total traded volume of 1.59 million. The stock currently has its 52-Week top value of $10.95 and 52-week down value of $5.57. The price to book (P/B) ratio of the company is 2.79. Its previous closing price was recorded at $8.88.
For the current Fiscal Quarter, 7 analysts have given an Average earnings estimate of $-0.15 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-0.16 while High Estimate is $-0.15. The Previous Year EPS of this Quarter is $-0.25.
According to 6 analysts, an Average Revenue Estimate of the current Fiscal quarter is $NaN. According to them, the Low Revenue estimate is $NaN and High Revenue estimate is $NaN.
The Company currently has High Price Target of $16. The Low and Mean Price Targets are $7 and $10 respectively. These price targets are set after consensus analysis of 6 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 2 analysts have given this stock as Strong Buy where 1 issued Buy, 3 analysts think that it’s a Hold, 1 told Underperform and0 assigned Sell rating.